A share price of Biomarin Pharmaceutical Inc [BMRN] is currently trading at $70.54, up 0.07%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BMRN shares have lost -0.91% over the last week, with a monthly amount glided 11.09%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Biomarin Pharmaceutical Inc [NASDAQ: BMRN] stock has seen the most recent analyst activity on February 24, 2025, when Oppenheimer upgraded its rating to a Outperform but kept the price target unchanged to $98 for it. Previously, Wolfe Research started tracking the stock with Outperform rating on November 15, 2024, and set its price target to $95. On October 30, 2024, downgrade downgraded it’s rating to Mkt Perform. Bernstein upgraded its rating to a Outperform and raised its price target to $110 on August 20, 2024. Robert W. Baird downgraded its rating to Neutral for this stock on May 17, 2024, and downed its price target to $72. In a note dated May 14, 2024, Evercore ISI initiated an Outperform rating and provided a target price of $113 on this stock.
Biomarin Pharmaceutical Inc experienced fluctuations in its stock price throughout the past year between $60.63 and $94.85. Currently, Wall Street analysts expect the stock to reach $86 within the next 12 months. Biomarin Pharmaceutical Inc [NASDAQ: BMRN] shares were valued at $70.54 at the most recent close of the market. An investor can expect a potential return of 21.92% based on the average BMRN price forecast.
Analyzing the BMRN fundamentals
Trailing Twelve Months sales for Biomarin Pharmaceutical Inc [NASDAQ:BMRN] were 2.84B which represents 14.29% growth. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at 0.16%, Pretax Profit Margin comes in at 0.19%, and Net Profit Margin reading is 0.15%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.08 and Total Capital is 0.07. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 69.84 points at the first support level, and at 69.15 for the second support level. However, for the 1st resistance point, the stock is sitting at 71.03, and for the 2nd resistance point, it is at 71.52.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Biomarin Pharmaceutical Inc [NASDAQ:BMRN] is 5.33. In addition, the Quick Ratio stands at 3.29 and the Cash Ratio stands at 1.55. Considering the valuation of this stock, the price to sales ratio is 4.74, the price to book ratio is 2.38 and price to earnings (TTM) ratio is 32.07.
Transactions by insiders
Recent insider trading involved Guyer Charles Greg, EVP, Chief Technical Officer, that happened on Mar 06 ’25 when 7034.0 shares were sold. Officer, Guyer Charles Greg completed a deal on Mar 06 ’25 to buy 7034.0 shares. Meanwhile, GVP, Chief Accounting Officer Burkhart Erin sold 1344.0 shares on Feb 24 ’25.
